Literature DB >> 9002386

Very low incidence rates of community-acquired hepatitis C virus infection in company employees, long-term inpatients, and blood donors in Japan.

F Sasaki1, J Tanaka, T Moriya, K Katayama, M Hiraoka, K Ohishi, H Nagakami, S Mishiro, H Yoshizawa.   

Abstract

To assess the contemporary rate of hepatitis C virus (HCV) propagation in Japanese community, we conducted a sentinel study on three groups of people: company employees, long-term inpatients, and blood donors. A total of 3079 company employees negative for anti-HCV were followed thereafter, and seroconversion to anti-HCV was found in 5 per 5786 person-years. None of them was positive for HCV RNA. In the group of 703 long-term inpatients (25 of whom were initially positive for anti-HCV) none showed seroconversion to anti-HCV per 2712 person-years. As for 114,266 repeated blood donors who were initially antibody-negative, 227 became anti-HCV positive later. Of these seroconverted donors, 83 were found to have anti-HCV with titers of 2(6) or greater. HCV RNA was positive in only 3 of them. Thus, the incidence rates of acquired HCV viremia in these three groups were 0 for both company employees and long-term inpatients, and 1.78 (95% C.I.: 0.37-5.19) per 100,000 person-years in blood donors. These results suggest that community-acquired HCV infection is now rare in Japan, and that even if it occurred it hardly leads to persistent viremia.

Entities:  

Mesh:

Year:  1996        PMID: 9002386     DOI: 10.2188/jea.6.198

Source DB:  PubMed          Journal:  J Epidemiol        ISSN: 0917-5040            Impact factor:   3.211


  3 in total

1.  Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees.

Authors:  V Sypsa; E Hadjipaschali; A Hatzakis
Journal:  Eur J Epidemiol       Date:  2001       Impact factor: 8.082

2.  The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area.

Authors:  Naota Taura; Nobuyoshi Fukushima; Hiroshi Yastuhashi; Yuko Takami; Masataka Seike; Hiroshi Watanabe; Toshihiko Mizuta; Yutaka Sasaki; Kenji Nagata; Akinari Tabara; Yasuji Komorizono; Akinobu Taketomi; Shuichi Matsumoto; Tsutomu Tamai; Toyokichi Muro; Kazuhiko Nakao; Kunitaka Fukuizumi; Tatsuji Maeshiro; Osami Inoue; Michio Sata
Journal:  Med Sci Monit       Date:  2011-02

Review 3.  Countermeasures against viral hepatitis B and C in Japan: An epidemiological point of view.

Authors:  Junko Tanaka; Tomoyuki Akita; Ko Ko; Yoshihiko Miura; Masahiro Satake
Journal:  Hepatol Res       Date:  2019-08-22       Impact factor: 4.288

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.